| 101 |
26411431 | Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial. | 2015 Dec |
1 |
| 102 |
26516441 | Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis. | 2015 Oct |
1 |
| 103 |
27512786 | Diagnosis and Treatment Modalities of Symptomatic Polycystic Kidney Disease | 2015 Nov |
1 |
| 104 |
24048380 | Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. | 2014 Apr |
1 |
| 105 |
24240509 | Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. | 2014 May |
1 |
| 106 |
24570071 | Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. | 2014 May |
1 |
| 107 |
24678622 | Tolvaptan for the treatment of liver cirrhosis oedema. | 2014 Jul |
1 |
| 108 |
24706579 | Review of tolvaptan for autosomal dominant polycystic kidney disease. | 2014 Jun |
1 |
| 109 |
24743526 | [Clinical effects of tolvaptan for patients with stage 4-5 chronic kidney disease in cardiac surgery]. | 2014 Mar |
1 |
| 110 |
24954239 | Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. | 2014 |
2 |
| 111 |
25008484 | Novel diuretic strategies for the treatment of heart failure in Japan. | 2014 |
1 |
| 112 |
25179972 | Case report: new treatment with Tolvaptan for heart failure after cardiac surgery. | 2014 Aug |
1 |
| 113 |
25383228 | Low-dose tolvaptan for the treatment of dilutional hyponatremia in cirrhosis: a case report and literature review. | 2014 |
1 |
| 114 |
30534332 | Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy. | 2014 Jun |
1 |
| 115 |
22884529 | Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan. | 2013 Apr |
2 |
| 116 |
23274625 | Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study. | 2013 Jan 15 |
1 |
| 117 |
23297121 | Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation. | 2013 Feb |
1 |
| 118 |
23371016 | Letter in response to the recently published review: hyponatremia in cirrhosis and end-stage liver disease--treatment with the vasopressin v2-receptor antagonist tolvaptan. | 2013 Mar |
1 |
| 119 |
23483323 | The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. | 2013 Dec |
1 |
| 120 |
23676370 | Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. | 2013 |
1 |
| 121 |
23736843 | Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. | 2013 Jul |
1 |
| 122 |
24142853 | Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. | 2013 Dec |
1 |
| 123 |
30546768 | Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide. | 2013 Nov |
2 |
| 124 |
22027579 | Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. | 2012 Mar |
1 |
| 125 |
22130104 | Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men. | 2012 Apr |
1 |
| 126 |
22257581 | Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. | 2012 Feb |
1 |
| 127 |
22487409 | [Diagnostics and new treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH)]. | 2012 Apr 9 |
1 |
| 128 |
22722264 | Long-term treatment of hyponatremic patients with nephrogenic syndrome of inappropriate antidiuresis: personal experience and review of published case reports. | 2012 |
1 |
| 129 |
22732834 | Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan. | 2012 Nov |
2 |
| 130 |
21317283 | Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. | 2011 May |
1 |
| 131 |
22103869 | Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion. | 2011 Dec |
1 |
| 132 |
22120092 | Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). | 2011 Dec |
1 |
| 133 |
22120093 | Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study. | 2011 Dec |
1 |
| 134 |
22120094 | Phase III clinical pharmacology study of tolvaptan. | 2011 Dec |
1 |
| 135 |
20205486 | Tolvaptan. | 2010 Mar 5 |
1 |
| 136 |
20387081 | A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. | 2010 Sep |
1 |
| 137 |
20467590 | Tolvaptan for the treatment of hyponatremia and congestive heart failure. | 2010 Mar |
1 |
| 138 |
20637957 | Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review. | 2010 Jun |
1 |
| 139 |
19644472 | Tolvaptan. | 2009 Aug |
1 |
| 140 |
19007589 | Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. | 2008 Nov 4 |
2 |
| 141 |
20694082 | Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. | 2008 Jun |
1 |
| 142 |
17384437 | Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. | 2007 Mar 28 |
1 |
| 143 |
17384438 | Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. | 2007 Mar 28 |
1 |
| 144 |
17445084 | Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. | 2007 Spring |
1 |
| 145 |
17445935 | Vaptans: a promising therapy in the management of advanced cirrhosis. | 2007 Jun |
2 |
| 146 |
17543634 | Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. | 2007 Jun 5 |
1 |
| 147 |
17660019 | Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia. | 2007 Aug |
1 |
| 148 |
18037090 | Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure? | 2007 Dec |
1 |
| 149 |
16563917 | Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. | 2006 Apr 1 |
1 |
| 150 |
16782344 | A flexible approach for the preparation of substituted benzazepines: application to the synthesis of tolvaptan. | 2006 Sep 15 |
1 |